EGFR and esophageal squamous cell carcinoma: Subsequently, pan-EGFR antibodies significantly reduced the residual disease.186 To test the effect and mechanisms of EGFR-TKI on esophageal squamous cell carcinoma (ESCC), Liu et al. treated ESCC PDX models with afatinib and examined the underlying mechanism.